Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

Dual thrombolytic therapy with mutant pro-urokinase and small bolus alteplase for ischemic stroke (DUMAS): study protocol for a multicenter randomized controlled phase II trial

Abstract Background The effectiveness of alteplase for ischemic stroke treatment is limited, partly due to the occurrence of intracranial and extracranial hemorrhage. Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction with alteplase. Therefore, this trea...

Full description

Bibliographic Details
Main Authors: Nadinda A. M. van der Ende, Bob Roozenbeek, Lucas E. M. Smagge, Sven P. R. Luijten, Leo A. M. Aerden, Petra Kraayeveld, Ido R. van den Wijngaard, Geert J. Lycklama à Nijeholt, Heleen M. den Hertog, H. Zwenneke Flach, Alexis C. Wallace, Victor Gurewich, Gregory J. del Zoppo, William J. Meurer, Hester F. Lingsma, Aad van der Lugt, Diederik W. J. Dippel, on behalf of the DUMAS Investigators
Format: Article
Language:English
Published: BMC 2022-08-01
Series:Trials
Subjects:
Thrombolytic treatment
Mutant pro-urokinase
Alteplase
Ischemic stroke
Randomized controlled trial
Online Access:https://doi.org/10.1186/s13063-022-06596-z

Internet

https://doi.org/10.1186/s13063-022-06596-z

Similar Items